Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.68 |
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268719 | 0.90 | MAOB (0.81) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL9939705 | 0.87 | ALOX5 (0.76) | MAOBMAOAALOX5LCKMEN1 | |
| SCHEMBL6507891 | 0.85 | MAOB (0.64) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL80829 | 0.85 | MAOB (0.68) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL29411728 | 0.85 | MAOB (0.68) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL28237963 | 0.84 | MAOB (0.72) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL28182081 | 0.84 | MAOB (0.79) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL5329319 | 0.84 | MAOB (0.72) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL7285169 | 0.84 | MAOB (0.62) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL1770370 | 0.83 | TP53 (0.50) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328855-A1 | NOVEL TETRACYCLIC 4-OXO-PYRIDINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2018-06-06 | — | — | EP | disclosed |
| EP-3256471-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-3215504-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017017042-A1 | NOVEL TETRACYCLIC 4-OXO-PYRIDINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-02 | — | — | WO | disclosed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| WO-2016128335-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016071215-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| EP-1765792-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF STEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | Sterix Limited (GB) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005115996-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF SEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | STERIX LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050009830-A1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY. | 2005-01-13 | — | — | US | disclosed |
| US-6355813-B1 | INTERMEDIATES USEFUL IN PREPARING THESE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6114549-A | Process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009830-A1 | Heterocyclic cytotoxic agents | CCNE1, RB1, CCNA1 | MAOB 2542/4885BCHE 2696/4885CYP4F2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.